Finasteride (1 mg) and dutasteride (0.5 mg) both treat hair loss by blocking DHT, but differ in strength, side effect profile, and approval status. Finasteride is a first-line option; dutasteride is stronger, works faster, but has higher side effect risk and is off-label in the U.S. Start with finasteride and switch if needed. Always consult a doctor.
Finasteride (1 mg) | Dutasteride (0.5 mg) | |
What it does | Switches off one DHT-making enzyme | Switches off two DHT-making enzymes |
Who it suits | First-timers & most early-stage users | People who didn’t respond to finasteride or have fast/aggressive loss |
When you’ll notice change | 3-6 months, keeps getting better—sometimes for years | 3-4 months, often a bit quicker/stronger |
Sex-related side-effects | ~3–4 % of users | ~9 % of users |
Regulatory status | FDA-approved for hair loss since 1998 | FDA-approved for prostate; used “off-label” for hair in the US (fully approved in KR/JP/TW) |
Bottom line: Try finasteride first; switch to dutasteride if the results plateau or loss is very aggressive. Either way, stay consistent and work with your doctor.
Finasteride 1 mg | Dutasteride 0.5 mg | |
5-α-reductase isoforms blocked | Type II only | Type I and II |
Average serum DHT reduction | ~70 % | ~98 % |
Key clinical data | 48 % regrowth @ 1 yr, 66 % @ 2 yrs; 83 % halted loss | Superior hair-count & BASP score vs finasteride @ 24 wks |
Long-term evidence | 91.5 % improved, 99.1 % maintained baseline after 10 yrs | Finasteride non-responders gained density +10.3 % @ 6 mo |
Most common adverse events | Sexual: libido ↓, erectile dysfunction, ejaculation change (~3-4 %) | Sexual: libido ↓, erectile dysfunction (~9 %); reversible semen changes |
FDA status for AGA | Approved (1998) | Off-label in US; approved in KR/JP/TW |
Best suited for | First-line therapy, early-stage loss, risk-tolerant users | Finasteride non-responders, aggressive loss, maximal DHT suppression |
Finasteride blocks type II 5-α-reductase. Although serum DHT falls ~70 %, what matters is DHT inside the dermal papilla (DP), the engine room of the follicle, where type II dominates. In cultured DP cells, just 1 nM finasteride cuts DHT by ~86 %.¹
Dutasteride blocks both type I and II enzymes, lowering serum DHT by ~98 %. Because type I is less abundant in the DP, the “extra” reduction is smaller at the follicle level than the serum numbers suggest, yet still clinically useful for some men.
Finasteride 1 mg | Dutasteride 0.5 mg | |
Dose & timing | 1 mg tablet once daily (alternate-day dosing has shown similar 12-month results in one study) | 0.5 mg capsule once daily |
Visible change | 3-6 months; many users keep improving for several years | 3-4 months; continues improving ≤ 12 months (and sometimes longer) |
Missed doses | One or two missed tablets are harmless because the 5-α-reductase enzyme itself turns over slowly | Half-life ≈ 5 weeks, but daily dosing is still recommended |
Phase III trials (N = 1,879): 48 % of men showed visible regrowth at 1 year and 66 % at 2 years, vs 7 % on placebo. 83 % had no further loss at 2 years.
10-year Japanese follow-up (N = 532): 91.5 % improved hair density, and 99.1 % maintained or improved Norwood-Hamilton class.
Randomised dose-ranging trials: 0.5 mg dutasteride increased hair count by up to 18.67 hairs/cm² vs 14.92 hairs/cm² for 1 mg finasteride at 24 weeks.
Finasteride non-responder switch study: Density +10.3 %, thickness +18.9 % after 6 months on dutasteride.
Finasteride 1 mg | Dutasteride 0.5 mg | |
Sexual adverse events | ~3.8 % (vs 2.1 % placebo): decreased libido, erectile dysfunction, ejaculation changes | ~9 % (vs 5.7 % placebo): similar sexual symptoms; most occur in first 3 months |
Other adverse events ≥1 % | None significant | Breast tenderness 1.9 % vs 1 % placebo; reversible semen changes |
Pregnancy precautions | Women who are or may become pregnant must not handle crushed tablets | Same, plus defer blood donation 6 months after last dose (longer half-life) |
Good news: Most adverse events resolve over time with continued therapy or disappear entirely after discontinuation.
Finasteride 1 mg (Propecia® & generics): FDA-approved for male androgenetic alopecia since 1998; widely available internationally.
Dutasteride 0.5 mg (Avodart® & generics): FDA-approved for benign prostatic hyperplasia (BPH); prescribed off-label for hair loss in the U.S., but officially approved for androgenetic alopecia in South Korea, Japan, and Taiwan.
Scenario | Recommended Approach |
First-time oral therapy, early or moderate hair loss, lower risk tolerance | Start with finasteride 1 mg |
Minimal response after 12 months of finasteride | Switch to dutasteride 0.5 mg |
Rapid, aggressive loss at temples & vertex | Consider trying dutasteride first with physician oversight |
Actively trying to conceive in next 6 months | Postpone systemic therapy; explore topical nanocarriers, microneedling, or PRP |
Be consistent: steady suppression > perfect daily streaks.
Stack proven options: add 5 % topical minoxidil, T3, or (soon) HairDAO’s liposomal-dutasteride for extra growth.
Track progress: photos every 3 months or schedule a trichoscan by emailing support@anagen.xyz.
Report side-effects early: simple tweaks (dose-splitting, alternate-day dosing) often help.
Note on lifestyle: General health is great, but male-pattern hair loss is almost always genetic/hormonal; diet, gyms, or meditation alone rarely move the needle without medication.
Stay consistent: daily dosing keeps DHT suppressed.
Combine proven treatments: add 5 % minoxidil foam or soon HairDAO’s proprietary liposomal dutasteride topical for synergy.
Document your journey: take well-lit photos every 3 months; subtle progress adds up. Alternatively email support@anagen.xyz to schedule a trichoscan appointment.
Report adverse events promptly: dose-splitting or schedule tweaks often fix issues.
Lifestyle matters: optimize sleep, protein intake, vitamin D, iron, and manage stress for healthier hair.
Join the Anagen & HairDAO Community
Share before-and-after photos on Discord, Instagram, X, & TikTok with #AnagenHairGrowth
Discuss protocols and new research in our Discord with our community.
Book a complimentary 15-minute telehealth call with me (Andrew Verbinnen, Anagen co-founder) to customize your plan.
Let’s get HAIRy together!
Eicheler W, Huth A, Happle R & Hoffmann R (1996). RNA-levels of 5α-reductase and androgen receptor in human skin, hair follicles and follicle-derived cells. In: Van Neste DJJ & Randall VA (Editors), Hair Research for the Next Millenium. Elsevier Science, Amsterdam, 327-331.
This content is for informational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Finasteride (1 mg) and dutasteride (0.5 mg) both treat hair loss by blocking DHT, but differ in strength, side effect profile, and approval status. Finasteride is a first-line option; dutasteride is stronger, works faster, but has higher side effect risk and is off-label in the U.S. Start with finasteride and switch if needed. Always consult a doctor.
Finasteride (1 mg) | Dutasteride (0.5 mg) | |
What it does | Switches off one DHT-making enzyme | Switches off two DHT-making enzymes |
Who it suits | First-timers & most early-stage users | People who didn’t respond to finasteride or have fast/aggressive loss |
When you’ll notice change | 3-6 months, keeps getting better—sometimes for years | 3-4 months, often a bit quicker/stronger |
Sex-related side-effects | ~3–4 % of users | ~9 % of users |
Regulatory status | FDA-approved for hair loss since 1998 | FDA-approved for prostate; used “off-label” for hair in the US (fully approved in KR/JP/TW) |
Bottom line: Try finasteride first; switch to dutasteride if the results plateau or loss is very aggressive. Either way, stay consistent and work with your doctor.
Finasteride 1 mg | Dutasteride 0.5 mg | |
5-α-reductase isoforms blocked | Type II only | Type I and II |
Average serum DHT reduction | ~70 % | ~98 % |
Key clinical data | 48 % regrowth @ 1 yr, 66 % @ 2 yrs; 83 % halted loss | Superior hair-count & BASP score vs finasteride @ 24 wks |
Long-term evidence | 91.5 % improved, 99.1 % maintained baseline after 10 yrs | Finasteride non-responders gained density +10.3 % @ 6 mo |
Most common adverse events | Sexual: libido ↓, erectile dysfunction, ejaculation change (~3-4 %) | Sexual: libido ↓, erectile dysfunction (~9 %); reversible semen changes |
FDA status for AGA | Approved (1998) | Off-label in US; approved in KR/JP/TW |
Best suited for | First-line therapy, early-stage loss, risk-tolerant users | Finasteride non-responders, aggressive loss, maximal DHT suppression |
Finasteride blocks type II 5-α-reductase. Although serum DHT falls ~70 %, what matters is DHT inside the dermal papilla (DP), the engine room of the follicle, where type II dominates. In cultured DP cells, just 1 nM finasteride cuts DHT by ~86 %.¹
Dutasteride blocks both type I and II enzymes, lowering serum DHT by ~98 %. Because type I is less abundant in the DP, the “extra” reduction is smaller at the follicle level than the serum numbers suggest, yet still clinically useful for some men.
Finasteride 1 mg | Dutasteride 0.5 mg | |
Dose & timing | 1 mg tablet once daily (alternate-day dosing has shown similar 12-month results in one study) | 0.5 mg capsule once daily |
Visible change | 3-6 months; many users keep improving for several years | 3-4 months; continues improving ≤ 12 months (and sometimes longer) |
Missed doses | One or two missed tablets are harmless because the 5-α-reductase enzyme itself turns over slowly | Half-life ≈ 5 weeks, but daily dosing is still recommended |
Phase III trials (N = 1,879): 48 % of men showed visible regrowth at 1 year and 66 % at 2 years, vs 7 % on placebo. 83 % had no further loss at 2 years.
10-year Japanese follow-up (N = 532): 91.5 % improved hair density, and 99.1 % maintained or improved Norwood-Hamilton class.
Randomised dose-ranging trials: 0.5 mg dutasteride increased hair count by up to 18.67 hairs/cm² vs 14.92 hairs/cm² for 1 mg finasteride at 24 weeks.
Finasteride non-responder switch study: Density +10.3 %, thickness +18.9 % after 6 months on dutasteride.
Finasteride 1 mg | Dutasteride 0.5 mg | |
Sexual adverse events | ~3.8 % (vs 2.1 % placebo): decreased libido, erectile dysfunction, ejaculation changes | ~9 % (vs 5.7 % placebo): similar sexual symptoms; most occur in first 3 months |
Other adverse events ≥1 % | None significant | Breast tenderness 1.9 % vs 1 % placebo; reversible semen changes |
Pregnancy precautions | Women who are or may become pregnant must not handle crushed tablets | Same, plus defer blood donation 6 months after last dose (longer half-life) |
Good news: Most adverse events resolve over time with continued therapy or disappear entirely after discontinuation.
Finasteride 1 mg (Propecia® & generics): FDA-approved for male androgenetic alopecia since 1998; widely available internationally.
Dutasteride 0.5 mg (Avodart® & generics): FDA-approved for benign prostatic hyperplasia (BPH); prescribed off-label for hair loss in the U.S., but officially approved for androgenetic alopecia in South Korea, Japan, and Taiwan.
Scenario | Recommended Approach |
First-time oral therapy, early or moderate hair loss, lower risk tolerance | Start with finasteride 1 mg |
Minimal response after 12 months of finasteride | Switch to dutasteride 0.5 mg |
Rapid, aggressive loss at temples & vertex | Consider trying dutasteride first with physician oversight |
Actively trying to conceive in next 6 months | Postpone systemic therapy; explore topical nanocarriers, microneedling, or PRP |
Be consistent: steady suppression > perfect daily streaks.
Stack proven options: add 5 % topical minoxidil, T3, or (soon) HairDAO’s liposomal-dutasteride for extra growth.
Track progress: photos every 3 months or schedule a trichoscan by emailing support@anagen.xyz.
Report side-effects early: simple tweaks (dose-splitting, alternate-day dosing) often help.
Note on lifestyle: General health is great, but male-pattern hair loss is almost always genetic/hormonal; diet, gyms, or meditation alone rarely move the needle without medication.
Stay consistent: daily dosing keeps DHT suppressed.
Combine proven treatments: add 5 % minoxidil foam or soon HairDAO’s proprietary liposomal dutasteride topical for synergy.
Document your journey: take well-lit photos every 3 months; subtle progress adds up. Alternatively email support@anagen.xyz to schedule a trichoscan appointment.
Report adverse events promptly: dose-splitting or schedule tweaks often fix issues.
Lifestyle matters: optimize sleep, protein intake, vitamin D, iron, and manage stress for healthier hair.
Join the Anagen & HairDAO Community
Share before-and-after photos on Discord, Instagram, X, & TikTok with #AnagenHairGrowth
Discuss protocols and new research in our Discord with our community.
Book a complimentary 15-minute telehealth call with me (Andrew Verbinnen, Anagen co-founder) to customize your plan.
Let’s get HAIRy together!
Eicheler W, Huth A, Happle R & Hoffmann R (1996). RNA-levels of 5α-reductase and androgen receptor in human skin, hair follicles and follicle-derived cells. In: Van Neste DJJ & Randall VA (Editors), Hair Research for the Next Millenium. Elsevier Science, Amsterdam, 327-331.
This content is for informational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
